Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Biodesix, Inc. BDSX

Healthcare — Diagnostics & Research
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
3.12
Total sells
0.12
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — 2 — — — — — — 2 —
Sell — 5 — 5 10 — — — — — — —
Insider Ownership
54.45%

Capital & Financial Ratios

Market Cap
303.98
Revenue
102.94
Net Income
(27.76)
Free Cash Flow
(20.40)
Net Debt
16.82
Current Ratio
2.85
Debt/Equity
5.12
P/E ratio
0.00
P/S ratio
2.92
P/B ratio
32.88
Past 5Y EPS Growth
69.26%
This Y EPS Growth
42.77%
Next Y EPS Growth
37.58%
Next 5Y EPS Growth
39.91%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 26.28 26.25 18.99 30.00
Receivables 7.68 8.60 9.04 9.11
Inventory — — — —
Other 5.72 4.64 4.50 4.46
39.68 39.48 32.52 43.57
2023 2024 2025 Q'26
Payables 2.93 2.19 3.08 2.16
ST’ Debt 0.05 0.02 0.01 —
Other 22.15 0.64 0.99 0.91
33.42 14.32 17.44 15.29
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡ ‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 25.56 26.86 — —
—
’25 17.96 20.02 21.77 28.76
88.50
’24 14.82 17.93 18.15 20.43
71.32
’23 9.06 11.87 13.49 14.67
49.09
’22 6.55 10.95 11.11 9.61
38.21
’21 28.87 11.89 6.53 7.22
54.51
’20 5.10 4.24 9.19 27.03
45.56
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (10.17) (1.56) — —
—
’25 (8.60) (6.57) (8.88) 0.78
(23.27)
’24 (15.31) (18.57) (10.67) (4.10)
(48.65)
’23 (7.69) 0.94 (3.84) (12.28)
(22.87)
’22 (13.10) (9.59) (10.33) (11.95)
(44.97)
’21 (11.33) 1.09 (7.79) (10.20)
(28.22)
’20 (4.54) (4.30) (3.77) (8.76)
(21.37)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (10.31) (1.82) — —
—
’25 (8.74) (6.66) (8.95) 0.67
(23.67)
’24 (15.58) (20.57) (10.96) (4.98)
(52.09)
’23 (15.39) (5.56) (9.72) (15.28)
(45.93)
’22 (13.45) (9.97) (11.15) (13.93)
(48.51)
’21 (11.84) 0.74 (8.83) (10.84)
(30.77)
’20 (4.68) (4.48) (5.09) (9.30)
(23.54)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.81) (0.71) — —
—
’25 (1.60) (1.60) (1.16) (0.49)
(4.67)
’24 (2.80) (1.60) (1.40) (1.20)
(6.60)
’23 (4.80) (3.40) (2.80) (2.00)
(12.80)
’22 (10.00) (8.00) (6.80) (7.00)
(31.00)
’21 (5.20) (8.20) (8.20) (9.80)
(31.60)
’20 (0.37) (0.31) (638.60) (5.00)
(129.60)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — ‡‡‡‡‡ ‡‡‡‡ 19.10 20.60 22.20 3.44 — — —
Low Price
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 119.94 50.60 44.20 31.00 — — —
High Price
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 245 217 273 334 — — —
Employees
— — ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.16 0.23 0.26 0.26 — — —
Revenue/Emp
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 38.21 49.09 71.32 88.50 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 62.96% 73.50% 78.17% 81.11% — — —
Gross Margin
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (65.45) (52.15) (42.93) (35.26) — — —
EBT
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (171.27%) (106.23%) (60.19%) (39.85%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (65.45) (52.15) (42.93) (35.26) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.96 10.66 8.16 7.01 — — —
Depreciation
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 18.15 11.96 11.02 11.72 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (31.00) (12.80) (6.60) (4.67) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (21.36) (5.57) (7.52) (3.08) — — —
Cash Flow/Sh
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.68) (5.62) (0.53) (0.05) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (23.04) (11.19) (8.05) (3.14) — — —
Free CF/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.79 1.12 3.23 (0.33) — — —
Book Value/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.11 4.11 6.47 7.55 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.26 2.98 2.78 0.58 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.19 31.91 9.48 0.00 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.79 3.16 2.92 0.90 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.41) (3.38) (4.00) (3.37) — — —
EV/FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (44.97) (22.87) (48.65) (23.27) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.53) (23.06) (3.44) (0.40) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (48.51) (45.93) (52.09) (23.67) ‡‡‡‡‡ — —
FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 30.50 6.27 25.17 15.08 — — —
Working Cap'
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 25.05 35.28 36.43 47.45 — — —
Total Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (18.03) 8.99 10.18 28.46 — — —
Net Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 20.61 4.58 20.88 (2.46) — — —
Sh' Equity
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (77.45%) (54.32%) (43.73%) (38.18%) — — —
ROA
— — ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡ (1,229.75%) (190.38%) (69.42%) (67.00%) — — —
ROIC
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (324.53%) (414.09%) (337.30%) (383.09%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Biodesix, Inc. (BDSX), a precision diagnostics firm focused on AI-driven blood tests for lung cancer and interstitial lung disease, demonstrates robust revenue acceleration, surging 45% year-over-year to $71.3 million in 2024 with a 30%+ CAGR since 2019, outpacing headcount growth and driving gross margins back toward 80%. This operational leverage, bolstered by FDA Breakthrough Designation for its Nodify platform and innovations like the 2023 VeriPath launch, signals a maturing model amid rising global lung cancer cases, with forecasts projecting continued expansion to $124 million by 2027.

Yet profitability remains elusive, with narrowing losses and a projected breakeven by 2025, though persistent cash burn—operating cash flow at -$48.6 million in 2024—and modest net debt of $10.2 million underscore balance sheet vulnerabilities in a competitive diagnostics landscape. Trading near multi-year lows, the stock appears deeply undervalued, with analyst targets implying over 200% upside and EV/sales compressing to 0.73x by 2027, far below peers.

Insider conviction shines through a key 10% holder’s massive share purchases dwarfing routine executive sales, reinforcing long-term potential amid reimbursement tailwinds and efficiency gains. While risks like payer pressures and R&D costs loom, BDSX’s trajectory offers cautious appeal for patient investors eyeing a biotech inflection.

Read full commentary →

Biodesix, Inc. (BDSX) Latest News

News by impact score

Fine-tune

18 Sep

3 , 12:11 PM
Biodesix (BDSX) stock receives a fair value boost driven by optimism on revenue growth and margin improvement. Analyst fair value increase reflects revenue and margin optimism that may moderately affect investor sentiment and near-term stock performance.

31 Aug

3 , 9:55 AM
Wall Street analysts forecast a 26.72% upside for Biodesix (BDSX) stock and question whether the shares can achieve that gain. Analyst price-target projections can shift short-term trading sentiment for Biodesix without changing its underlying operations or strategy.

12 Aug

3 transcript www.fool.com, 5:59 PM
Biodesix held its Q2 2026 earnings call to review quarterly financial results and business outlook. Earnings call provides quarterly results and guidance that can shift near-term investor sentiment and stock movement.

6 Aug

4 transcript , 1:08 AM
Biodesix Inc (BDSX) posted 34% revenue growth in Q2 2026 fueled by strong diagnostic sales. 34% revenue surge signals major positive shift in financial performance and market trajectory.

3 transcript app.moby.co, 8:30 AM
Biodesix, Inc. held its Q2 2026 earnings call covering financial results, operational updates and forward guidance. Quarterly earnings releases and guidance directly influence near-term stock valuation and investor positioning.

5 Aug

4 , 4:01 PM
Biodesix announces second quarter 2026 financial results and company highlights. Quarterly results release directly affects stock valuation and investor outlook.

3 transcript www.marketbeat.com, 7:04 PM
Biodesix Q2 earnings call highlights include revenue results, net losses, operational updates, and management outlook on testing volumes and partnerships. Q2 earnings provide performance data and guidance that may influence short-term sentiment without major strategic changes.

3 Jul

3 , 10:13 AM
Elevance seeks to recover $115 million via its CMS lawsuit with possible direct financial and operational effects on Biodesix. Lawsuit resolution could alter Biodesix revenue or liabilities but effects remain limited to one financial matter.

26 Jun

3 , 3:07 PM
Analysts raised Biodesix (BDSX) fair value estimate, citing support for the company's growth path. Analyst fair value upgrades can lift short-term investor sentiment and trading activity for Biodesix.

23 May

3 Insider Monkey, 8:16 AM
Canaccord Genuity raised its price target on Biodesix (BDSX) after increasing revenue assumptions for the company. Analyst price target increase on higher revenue forecasts indicates moderately improved near-term financial expectations for Biodesix.

11 May

3 GlobeNewswire, 9:17 AM
Biodesix announces presentations at ATS 2026 providing real-world clinical evidence and healthcare system economic value for Nodify Lung® testing strategy. ATS 2026 presentations on Nodify Lung's real-world evidence and economic value moderately strengthen Biodesix's product validation and market positioning.

7 May

4 Zacks, 9:55 AM
Wall Street analysts expect Biodesix (BDSX) stock to rally 103.33%, highlighting strong growth potential based on recent evaluations. Analysts' projection of 103.33% upside for BDSX could drive significant investor sentiment and stock trajectory shift.

4 May

4 app.moby.co, 8:16 PM
Biodesix, Inc. Q1 2026 earnings call summary details financial results, revenue growth, operational updates, and forward-looking guidance for the diagnostic company. Q1 earnings call summary discloses critical financial metrics, guidance, and strategic updates that significantly shape investor expectations and stock performance.

4 transcript www.fool.com, 6:26 PM
Biodesix (BDSX) released Q1 2026 earnings call transcript detailing quarterly financial results, operational updates, and forward guidance. Q1 2026 earnings transcript covers financial performance, revenue growth, and strategic outlook significantly influencing BDSX trajectory and investor sentiment.

4 transcript www.fool.com, 5:15 PM
Biodesix Inc. (BDSX) Q2 2025 earnings call transcript released, detailing quarterly financial results, operational updates, and forward guidance. Q2 2025 earnings call transcript covers financial performance, strategic initiatives, and guidance with potential to significantly sway investor sentiment and stock trajectory.

4 GlobeNewswire, 4:01 PM
Biodesix announced first quarter 2026 results, highlighting key financial and operational achievements. Quarterly earnings releases drive significant shifts in stock performance and investor outlook.

3 www.marketbeat.com, 6:17 PM
Biodesix, Inc. (BDSX) released Q1 earnings call highlights, covering financial results, operational updates, and future outlook for its diagnostic solutions. Q1 earnings highlights provide updates on financial performance and operations with moderately noticeable influence on market sentiment.

3 Zacks, 5:10 PM
Biodesix, Inc. (BDSX) reported a first-quarter net loss but surpassed revenue estimates. Q1 revenue beat despite net loss affects financial performance and investor sentiment moderately.

17 Apr

4 Simply Wall St., 9:06 AM
Recent shifts are reframing Biodesix (BDSX) investment story, highlighting changes in operations, market position, and growth prospects. Recent shifts represent major strategic changes that significantly alter BDSX's trajectory and investor sentiment.

6 Apr

3 GlobeNewswire, 11:43 AM
Biodesix announces posters and presentations at AACR 2026, highlighting novel diagnostic test discoveries and pipeline development advancements. AACR 2026 presentations showcase novel diagnostic discoveries and pipeline progress, moderately boosting innovation perception and investor sentiment.

20 Mar

4 GlobeNewswire, 8:06 AM
Biodesix announced publication of the largest lung nodule biomarker clinical validation study ever, demonstrating strong performance in identifying malignancy and supporting earlier lung cancer diagnosis. Largest-ever validation study strengthens Biodesix's diagnostic credibility, likely accelerating adoption and positively impacting revenue and stock performance.

19 Mar

3 , 9:55 AM
Wall Street analysts forecast an 86.45% upside for Biodesix (BDSX) stock, questioning whether it can realistically achieve this target amid current market conditions. Analyst consensus projecting 86.45% upside could moderately boost investor sentiment and short-term stock performance without fundamentally altering operations.

13 Mar

4 www.marketbeat.com, 1:14 AM
Biodesix highlighted strong momentum in its lung diagnostic test, 81% gross margins, and outlined a comprehensive growth plan at the Barclays Conference. 81% gross margins, lung test momentum, and growth plans signal major strategic advancements boosting financial health and investor sentiment.

6 Mar

4 www.marketbeat.com, 7:38 AM
Biodesix outlined growth plans for lung nodule diagnostics and a push into primary care at the TD Cowen Healthcare Conference. Strategic plans for lung nodule expansion and primary care entry represent major moves to broaden market reach and drive future revenue growth.

5 Mar

4 Simply Wall St., 8:09 AM
Biodesix (BDSX) investment narrative shifts positively after recent guidance update and analyst's new US$30 price target, highlighting improved outlook and growth potential. New US$30 price target post-guidance signals major bullish shift in investor sentiment and potential trajectory alteration.

3 Mar

4 Zacks, 9:55 AM
Wall Street analysts predict Biodesix (BDSX) stock could surge 111.62%, based on consensus price targets far exceeding current levels. Analyst consensus projects 111.62% upside for BDSX, signaling major positive shift in investor sentiment and potential market performance.

27 Feb

4 app.moby.co, 8:30 AM
Biodesix, Inc. (BDSX) Q4 2025 earnings call summary details financial results, revenue growth, product updates, and future guidance. Q4 earnings summaries disclose key financials and guidance that significantly shape BDSX's trajectory and investor sentiment.

4 GuruFocus.com, 12:04 AM
Biodesix Inc. (BDSX) reported strong revenue growth and strategic advancements in its Q4 2025 earnings call, highlighting improved financial performance and future initiatives. Strong revenue growth and strategic moves indicate significant positive shifts in financial health and market positioning.

26 Feb

4 transcript www.fool.com, 7:14 PM
Biodesix (BDSX) conducted its Q4 2025 earnings call, reviewing full-year financial results, revenue growth, product updates, and 2026 guidance amid diagnostic advancements. Q4 earnings transcript details financial performance, revenue beats, and forward guidance pivotal to BDSX's market trajectory.

4 www.marketbeat.com, 5:48 PM
Biodesix released highlights from its Q4 earnings call, detailing financial results, operational updates, and forward-looking guidance. Q4 earnings call highlights disclose financial performance, revenue growth, and strategic outlook that significantly influence BDSX trajectory and investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us